Fulgent Genetics, Inc.
FLGTDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 1 past
No catalysts found.
How FLGT's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
FID007 | Phase 2 | Head and Neck Squamous Cell Carcinoma | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Fulgent Genetics, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Fulgent Genetics, Inc.'s (FLGT) pipeline across Phase 2. Its lead program is FID007 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Fulgent Genetics, Inc.'s next FDA catalyst?→
Fulgent Genetics, Inc.'s (FLGT) next tracked catalyst is a Earnings expected July 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track FLGT biotech catalysts?→
Add FLGT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Fulgent Genetics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.